Journal of Clinical and Diagnostic Research (Feb 2019)

Adjuvant External Beam Radiotherapy with Concurrent Cisplatin after Resection of Gallbladder Cancer

  • Sunil Choudhary,
  • Neha Gupta,
  • Avipsa Das,
  • Nilesh Mani,
  • Rumita Singh,
  • Ritika Ranjan,
  • Neelam Lader,
  • Garima Jaiswal

DOI
https://doi.org/10.7860/JCDR/2019/40020.12559
Journal volume & issue
Vol. 13, no. 2
pp. XC01 – XC04

Abstract

Read online

Introduction: Loco-regional failure is a serious problem in patients of gallbladder cancer following radical cholecystectomy. However, due to its rare occurrence the role of adjuvant chemoradiotherapy is not well established. Aim: To evaluate the treatment outcomes of concurrent Cisplatin (CDDP) with External Beam Radiotherapy (EBRT) in patients of Gallbladder Cancer (GBC) after radical cholecystectomy. Materials and Methods: We retrospectively reviewed the medical records of 12 patients of GBC who were registered with us between January’ 2016 and January’ 2017 after curative cholecystectomy. Only stage II and III patients were selected. This cohort had adjuvant EBRT with 6 MV photon beam using 3D conformal radiotherapy technique. These patients were given concurrent CDDP 35 mg/m2 at a weekly interval. Results: The mean EBRT dose and CDDP cycle was 45 Gy and four respectively. All except one patient could complete the treatment completely. There were no major acute or late toxicities. The median follow-up period was 23.4 months for those who were alive. There were four failures: one local, one loco-regional and two distant. Overall Survival (OS) and Disease Free Survival (DFS) at 2-years were 75% and 72% respectively. Conclusion: Adjuvant EBRT with concurrent CDDP for stage II and III GBC was well tolerated and had survival outcome comparable to the previous studies.

Keywords